Management of dyslipidemia in elderly diabetic patients

Diabetes and Metabolism

Volumn 31, Issue SPEC. ISS. 2, 2005, Pages

  Verny, C ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Diabetes mellitus; Dyslipidemia; Elderly; Statin; Vascular risk

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; PRAVASTATIN; SIMVASTATIN;

AGING; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; MORBIDITY; MORTALITY; POPULATION GROWTH; PROPHYLAXIS; REVIEW;

EID: 30844447469     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(05)73655-7     Document Type: Review

References (57)

1. Meneilly GS, Tessier D. Diabetes in elderly adults, J Gerontol A Biol Sci Med Sci 2001;56:M5-M13.
2. Grimaldi A, Heurtier A. Epidémiologie des complications cardiovasculaires du diabète. Diabetes Metab 1999;25:12-20.
3. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 1998;21:1138-45.
4. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.
5. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995;38:1061-8.
6. Beks PJ, Mackaay AJC, de Neeling JND, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn Study. Diabetologia 1995;38:86-96.
7. Laakso M, Lehto S, Penttila I, Pyörälä K. Cardiovascular risk factors, lipids and insulin: lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30.
8. Turner RC, Millns H, Neil HAW, et al. United Kingdom Prospective Diabetes Study group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8.
9. Vergès BL. La dyslipidémie du diabétique. Revue des principales anomalies lipoprotéiques et de leurs conséquences sur les gros vaisseaux. Diabetes Metab 1999;25:32-40.
10. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001;358:351-5.
11. Volpato S, Zuliani G, Guralnik JM, Palmieri E, Fellin R. The inverse association between age and cholesterol level among older patients: the role of poor health status. Gerontology 2001;47:36-45.
12. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Colhoun HM, Betteridge JD, Durrington PN, et al ; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;354:685-96.
15. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993;153:1065-73.
16. Abbott RD, Curb JD, Rodriguez BL, et al. Age-related changes in risk factor effects on the incidence of coronary heart disease. Ann Epidemiol 2002;12:173-81.
17. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998;279:585-92.
18. Psaty BM, Anderson M, Kronmal RA, et al. The association between lipid levels and the risks of incident myocardial infarction, stroke and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 2004;52:1639-47.
19. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254-60.
20. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995;274:575-7.
21. Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001;285:2729-35.
22. Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-23.
23. Jonsson A, Sigvaldason H, Sigfusson N. Total cholesterol and mortality after age 80 years. Lancet 1997;350:1778-9.
24. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
25. Shepherd J, Cobbe M, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-7.
26. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol And Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996;335:1001-9.
27. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
28. Serruys PWJC, de Feyter P, Macaya C, et al; Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomised controlled trial. JAMA 2002;287:3215-22.
29. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs. usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
30. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
31. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.
32. Cheung BMY, Lauder IJ, Lau C-P, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-51.
33. Hunt D, Young P, Simes J, et al; LIPID Investigators. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001;134:931-40.
34. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-26.
35. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282:2340-6.
36. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
37. Pyörälä K, Pedersen TR, Kjekshus J, Faegeman O, Olsson AG, Thorgeirsson G; the Scandinavian Simvastatin Survival Study. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
38. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7.
39. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998;98:2513-9.
40. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-900.
41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
42. Tikkanen MJ, Laakso M, Ilmonen M, et al. Study Group. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998;21:477-81.
43. Rubins HB, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33.
44. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905-10.
45. Elkeles RS, Diamond JR, Poulter C, et al. SENDCAP Study Group. Cardiovascular outcomes in type 2 diabetes: a double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21:641-8.
46. Wagner AM, Jorba O, Bonet R, Ordonez-Llanos J, Perez A. Efficacity of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003;88:3212-7.
47. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.
48. The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI Study: a double-blind randomized placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41.
49. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
50. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients. The treatment-risk paradox, JAMA 2004;291:1864-70.
51. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61.
52. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons/results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997;45:8-14.
53. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
54. Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet 2004;364:641-2.
55. American Diabetes Association. Management of dyslipidemia in adultes with diabetes. Diabetes Care 2003;26:S83-S86.
56. AFSSAPS. Prise en charge thérapeutique du patient dyslipidémique. Recommandations, mars 2005. www.afssaps.sante.fr
57. California Healthcare Foundation/American Geriatrics Society Panel on improving care for elders with diabetes. Guidelines for improving the care of the older persons with diabetes mellitus. J Am Geriatr Soc 2003;51:S265-S280.